Rapidly growing mycobacteria (RGM) are environmental organisms capable of causing a wide spectrum of diseases. We identified 116 cancer patients with RGM. Mycobacterium mucogenicum was the leading cause of disease. Removal of the catheter correlated with significant decrease in the bacteremia relapse rate (P = .007). A median duration of 4 weeks of therapy produced a good outcome.
antimicrobial regimen, duration of therapy, and central venous catheter (CVC) management, remain unclear.
METHODS
This retrospective study was conducted at The University of Texas MD Anderson Cancer Center in Houston. We searched the microbiology database to identify patients with at least 1 positive blood culture for RGM during January 1998 through August 2011. Upon reviewing the electronic medical records, we evaluated patients' clinical signs and symptoms; laboratory, microbiologic, and antimicrobial data; and the presence of a CVC. In order to determine outcome, relapse, and complications, all patients were monitored for 3 months. The study was approved by our institutional review board.
Microbiologic Identification
The identification of RGM was obtained by performing polymerase chain reaction (PCR) and gene sequencing. In our experience, and that of several other research groups, sequencing the first 500-600 bp of the 16S gene is the most accurate, rapid, and cost-effective method to identify RGM. This technique entails 1 PCR and 1 sequencing reaction to identify a RGM and usually takes 1-3 days after culture recovery [12] .
Definitions
Patients with at least 1 positive blood culture for RGM were considered to have RGM bacteremia. Central line-associated bloodstream infection (CLABSI) was defined as a patient who has at least 1 positive blood culture with an RGM, as well as signs and symptoms of infection (eg, temperature of 38.3°C, chills, or hypotension), has an indwelling intravascular catheter that has been in place for at least 48 hours, and has no apparent source of a bloodstream infection, except for the intravascular catheter [13] .
Statistical Analysis
Descriptive statistics were calculated for patients' demographic and clinical characteristics. The χ 2 or Fisher exact test was used to compare categorical variables, as appropriate. Continuous variables were compared using Wilcoxon rank sum tests. All tests were 2-sided at a significance level of .05. The data analyses were performed using SAS version 9.1 (SAS Institute, Cary, North Carolina).
RESULTS

Patient Characteristics
We evaluated 119 individual patients who had at least 1 RGM-positive blood culture during January 1998 through August 2011. Three patients with concomitant infection at the time of presentation were excluded. The remaining 116 patients were included in the study. Of these, 111 (96%) patients had CLABSI. The demographic characteristics and clinical features are summarized in Table 1 . Mycobacterium mucogenicum, isolated from 45 patients (39%), was the leading cause of RGM bacteremia, followed by Mycobacterium fortuitum (21%), Mycobacterium abscessus (14%), Mycobacterium chelonae (12%), and Mycobacterium neoaurum (5%). The most susceptible RGM species was M. mucogenicum (Table 2) .
At diagnosis, a CVC was present in 111 (96%) patients; the CVC was removed from 87 (79%). Eighty-five patients (73%) received antibiotics in addition to removal of the catheter. The most frequently used antibiotic classes, alone or in combination, were macrolides (76% of cases) and quinolones (75%), followed by aminoglycosides (28%), carbapenems (28%), and tetracyclines (14%). Mitral valve endocarditis was diagnosed via transesophageal echocardiogram vegetation on the mitral valve, with 3 positive blood cultures for M. chelonae, without any concomitant positive blood culture for other organism.
Ninety-five patients were treated with a combination of ≥2 antimicrobial agents, while 12 received monotherapy. The median treatment duration was 4 weeks. The most frequently employed combination regimen consisted of a macrolide and a quinolone (60%). Other noted combinations included an aminoglycoside with either a macrolide (27%) or a quinolone (23%). Less frequently utilized regimens consisted of a carbapenem combined with a macrolide (22%) or a quinolone (20%). Thirty (26%) patients received a regimen that included amikacin.
Outcome
A favorable response occurred in 92 patients (96%). The median interval between initiation of antibiotic therapy and clearance of bacteremia was 3 days. Microbiological eradication rate by end of therapy was 100%. Relapse occurred in only 5 patients; the 87 patients who had their CVC removed had a significantly lower rate of relapse (n = 1 [1%]) than those patients (n = 23) who had their CVC exchanged or retained (relapse in 4 patients [17%]; P = .007) or the subset (n = 3) who had a catheter exchange (relapse in 2 patients [67%]; P = .002). The rate of intravascular complications was relatively low, with 1 case of mitral valve infective endocarditis caused by M. chelonae and 2 cases of septic thrombophlebitis. Overall, the mortality rate was 17%. None of the 7 intensive care unit admissions and none of the deaths were related to the RGM bloodstream infection.
DISCUSSION
We present the results of a large study of RGM bloodstream infections among cancer patients. The most commonly encountered mycobacterial species was M. mucogenicum, isolated in 39% of the patients; M. fortuitum, M. abscessus, M. chelonae, or M. neoaurum were implicated in approximately half of the cases. These results are similar to the findings in 151 cancer patients with RGM bloodstream infection identified by a recent review of the literature [6] .
The majority of the RGM were susceptible to amikacin. Mycobacterium mucogenicum was the most susceptible strain, whereas M. abscessus was the most resistant ( Table 2) . Mycobacterium abscessus is considered to be one of the most virulent and chemotherapy-resistant members of the RGM group [14] . Throughout the past several years, several mechanisms of resistances have been identified. The expression of an inducible erythromycin methylase gene (erm) or acquisition of a mutation in the rrl gene encoding the 23S ribosomal RNA (rRNA) peptidyltransferase may trigger resistance to the macrolides [15] [16] [17] . Furthermore, aminoglycoside resistance can also result from a mutation in the rrs gene affecting the 16S rRNA [18, 19] . Mycobacterium fortuitum, the second most frequently isolated species in our study, was usually susceptible to amikacin, ciprofloxacin, or trimethoprim-sulfamethoxazole, but it was resistant to clarithromycin in 37% of the cases. This can be explained by the fact that M. fortuitum and M. neoaurum may express an inducible erm gene [20, 21] (Table 3) . The use of combination antimicrobial regimens was superior to monotherapy, and tended to be associated with lower relapse rate. In accordance with other studies, and owing to the wide variance of susceptibility patterns among RGM species [6, 22] , at least 2 active antimicrobial agents should be used. Those regimens that included amikacin appear to be associated with lower relapse rate and better outcomes. As in previous studies [14, [22] [23] [24] , we found that most of the RGM species were susceptible to amikacin. Therefore, if the patient has no contraindications to intravenous amikacin, this agent may be considered in the initial empiric treatment regimen of RGM bacteremia.
Earlier studies have recommended removal of the CVC in patients with RGM CLABSI [8, 25] , and our results provide confirmation that removal of the catheter is associated with a decrease in the rate of bacteremia relapse (P = .007). In our study, 96% of the patients had a concomitant CVC and met the criteria for CLABSI, confirming that RGM bacteremia almost occurs in patients with an indwelling CVC [6, 25] . These findings correlate with the pathogenicity of the RGM species to form a microbial biofilm matrix on the surface of the indwelling catheters [8] [9] [10] . Therefore, unless the CVC is removed, it is not surprising that the dense biofilm formed on the CVC and embedded with RGM acts as a source for bacteremia.
This study has some limitations. First, data were obtained retrospectively, which enabled us to perform a thorough examination of patients' clinical signs and symptoms for infection. Second, patients were not on a well-defined clinical protocol requiring repeat blood cultures, which can lead to underestimation of the duration of the bacteremia and its relapse. Third, we were not able to perform a multivariate analysis in relapse controlling for potential confounders because of the small sample size (only 5 relapse cases). Fourth, all RGM were lumped together for analysis. However, each species may be associated with different virulence, which could impact outcomes. Regardless of these limitations, our data strongly support CVC removal in patients with RGM CLABSI. The retention or exchange of the CVC over a guidewire was associated with a significantly higher rate of relapse. In addition, patients treated with a combination of ≥2 antibiotics and/or a regimen that included amikacin had a better clinical outcome. On this basis, we recommend removal of the CVC and treatment with a combination antimycobacterial regimen for cancer patients with RGM bacteremia. Amikacin  98  100  100  92  100  80   Clarithromycin  84  100  63  93  75  80  Linezolid  82  92  100  20  ND  ND   Imipenem  74  100  63  17  58  100   Ciprofloxacin  73  86  96  7  50  80  TMP-SMZ  72  100  88  11  30  100   Cefoxitin  55  93  42  7  33  80   Tobramycin  46  69  100  23  20  100  Minocycline  42  61  42  8  14  80   Doxycycline  38  13  56  ND  40  ND Abbreviations: ND, not done; TMP-SMZ, trimethoprim-sulfamethoxazole.
